Press release
Illumina Announces Next Generation Products and Data at AGBT General Meeting to Advance Innovative Customer Solutions
SAN DIEGO, June 7, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today shared key
About this update from Illumina, Inc.
[{"type":"text","content":"SAN DIEGO, June 7, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today shared key customer-focused announcements and presentations it will make at the Advances in Genome Biology and Technology (AGBT) General Meeting, taking place June 6–9 in Orlando, Fla. Announcements will include new 2x300 base pair read lengths on NextSeq™ 1000 and 2000 systems, designed to expand the breadth of applications and support customers looking to scale from the MiSeq™ system. In addition, new data on Illumina's Infinity technology will be presented in one of the company's sessions as well as a presentation on Illumina's informatics solutions, including DRAGEN Bio-IT and Illumina Connected Analytics (ICA). Illumina will also convene and lead several more events and discussions at the conference about genomics innovation to help further foster industry collaboration and partnership.\n\n \n \n \n \n \n \n\n \n\"At Illumina, customers are at the center of what we do, and we are excited to connect with them at AGBT to unveil our next-generation genomics solutions and learn more about their specific needs and requirements,\" said Susan Tousi, Chief Commercial Officer at Illumina. \"AGBT represents a key opportunity for Illumina to continue driving innovations that accelerate personalized medicine far into the future with our many valued partners.\"\nNew, longer-read kit configurations\nExpected to be released later this year, the new 600 cycle kit on NextSeq 1000/2000 will deliver longer, paired-end 2x300bp reads and expand the breadth of applications ranging from metagenomics to immune-repertoire profiling. Data will be presented demonstrating NextSeq 2000 as a powerful, new tool to enable full-length V(D)J immune repertoire sequencing at scale to further understand the human immunome. \n\"The upcoming launch of our new NextSeq kits is another important step towards continuing to elevate sequencing to a new industry benchmark,\" said Alex Aravanis, SVP and Chief Technology Officer at Illumina. \"Greater gene sequencing depth and length, combined with advanced library preparation approaches, represent the next wave of technological advances in repertoire sequencing that will unlock the power of the genome to transform human health.\"\nNew data with Infinity Technology \nIn its June 8 s...